Individuals living alone experienced a heightened mortality rate from cancer and multiple other conditions. This highlights the importance of social support in patient outcomes.
FDA Actions and Treatment Shifts
The FDA expanded the approval of talazoparib plus enzelutamide for metastatic prostate cancer, including patients with homologous recombination repair mutations. Recent trends in prostate cancer management demonstrated a shift away from overdiagnosis and overtreatment, alongside updated guidance on shorter-course radiation therapy protocols. An actress died following a terminal rectal cancer diagnosis. A football coach died after a year of health issues including a spinal tumor diagnosis.
Diagnostic and Therapeutic Advances
Brain cancer diagnosis may be aided by cerebrospinal fluid DNA testing. An implantable drug-delivery device utilizing ultrasound for brain tumor treatment was explored. Patients with relapsed/refractory multiple myeloma showed significantly better progression-free survival with a bispecific antibody. Research revealed new clues regarding aggressive colorectal cancers in younger individuals. Earlier survivorship care was associated with improved outcomes in head and neck cancer. A strategy to reprogram the tumor microenvironment was investigated for pancreatic cancer. An investigational cancer vaccine targeting driver mutations showed a non-significant improvement in disease-free survival. Patients with cancer and mental health disorders experienced significantly higher mortality 2 to 5 years after their cancer diagnosis. The FDA continues to oversee drug approvals and safety monitoring.